



EY Entrepreneur  
of the year-2013



FROST & SULLIVAN  
Best Practices-2013



Business today/YES bank  
Excellence Awards-2013



**Date: 02.07.2021**

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**Subject: Clarification on Increase in Volume**

**Ref. No.: NSE/CM/Surveillance/10927**

Dear Sir / Madam,

With reference to the above mentioned letter, we would like to inform that there is no such announcement or price sensitive information, which is pending to be intimated by the Company to the stock exchanges concerning its performance/ operations.

We wish to reiterate and clarify that all the latest relevant information about the Company, which in our opinion may have a bearing on the price / volume behaviour in the scrip has already been disclosed to the Exchanges. Further, the Company is in compliance with the SEBI (Listing Obligations and disclosures Requirements) Regulations and shall keep the stock exchanges duly informed of all the price sensitive information(s) in future as well.

You are requested to take the above clarification on record.

**For Eris Lifesciences Limited**

**Milind Talegaonkar**

**Company Secretary & Compliance Officer**

**Registered & Corporate Office:**

8<sup>th</sup> Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867